Skip to main content

Biofourmis

By Adam Ang | 03:43 am | October 18, 2024
Also, JLK and Heuron have received regulatory clearances for their medical imaging AI in the US and South Korea.
By Jessica Hagen | 09:25 pm | August 30, 2023
Kuldeep Singh Rajput's departure comes just one month after the company laid off 120 employees.
By Jessica Hagen | 12:21 pm | July 24, 2023
The company let go of 48 workers in the U.S.
By Emily Olsen | 01:33 pm | March 27, 2023
Dr. Maulik Majmudar, chief medical officer and cofounder of Biofourmis, discusses why healthcare often struggles to address the consumer experience.
By Bill Siwicki | 01:34 pm | August 22, 2022
A clinician shortage crisis is on the horizon. Here are some ideas from a top expert on what can be done.  
By Emily Olsen | 11:16 am | August 10, 2022
Also, Northwestern University spinout Sibel Health raises $33 million, and real-world evidence startup Atropos Health scoops up $14 million.
By Emily Olsen | 11:15 am | April 26, 2022
Coming nearly two years after the company's $100 million Series C, Biofourmis tallied its total raise at $445 million.
By Emily Olsen | 02:48 pm | February 09, 2022
Biofourmis Care currently includes programs for heart failure, hypertension, diabetes, lipid management and atrial fibrillation.
By MobiHealthNews | 04:18 pm | May 11, 2021
Also: Santosh Mohan leaves MassGen Brigham for Moffitt Cancer Center and Zipari names C-suite hires. 
By Dave Muoio | 11:48 am | September 03, 2020
Biofourmis has restructured its business to pursue its original focus on data-driven patient monitoring alongside its more recent interest in standalone and companion digital therapeutics.